00380930552240 (باللغة العربية)
00380930552240 (باللغة العربية)
International Stem Cell Corporation from California will soon launch a clinical study of a novel treatment option for Parkinson’s disease with the use of pluripotent parthenogenetic stem cells.All news
Parkinson’s disease (PD) is a degenerative disorder of the central nervous system characterized by different neurological disturbances related to motor skills, balance, psychoemotional disturbances, cognitive impairment and social behavioral disorders. PD is a progressive disorder: with time the condition of the sufferer tends to gradually aggravate. PD incidence doesn’t depend on sex or race, social status or place of residence. Despite the prevailing opinion that PK is a disorder involving elderly people, the average age of PD diagnosis is 57 years. However, 10% of the diseased are people under 40. With the increase of life span and average age of the population the incidence of PD is expected to rise.
The symptoms of PD mainly result from degeneration of dopaminergic neurons – neurons of the brain that produce and accumulate dopamine. Dopamine is a neurotransmitter, i.e. chemical serving to relay electric impulses from neurons, and a hormone. Dopamine deficit results in impaired transmission of nervous impulses, thus causing such distinctive PD symptoms as tremor of hands and legs, jaws, facial muscles, slowed movements, muscle stiffness, difficulties to initiate a movement and keep balance. Losing expressed mimicry, PD patients can seem apathic (indifferent). Speech can become slurred and monotonous. Other PD symptoms include depression, anxiety, dementia (weakness of mind), difficulties in chewing and swallowing, appetite disturbances, hypersalivation, and bowel and urinary bladder disorders. Not all the above PD symptoms develop in each PD case.
The causes of PD have not been defined. Common causes of Parkinson’s diseases include combination of several factors, in particular:
Other causes of PD include cerebral atherosclerosis, head trauma, tumours, virus infections, etc.
Due to commonly slow progression, Parkinson’s disease at its early stages can be difficult to diagnose for several years. Typically, at the initial stage of Parkinson’s disease patients complain of some rigidity in the extremities, decreased joint flexibility, difficulty in walking and performing active movements. It is worth noting that PD progresses more rapidly in those who developed it at younger age.
Depending on how PD progresses at the advanced stages, the quality of PD sufferers’ life can significantly deteriorate. In severe disorders, such as disturbed swallowing or total immobilization and in case of impropriate nursing, such concomitant problems as respiratory disturbances, secondary infection, etc., can develop. In average, Parkinson’s disease cuts down the life expectancy by 3-9 years.
Cell Therapy Center EmCell offers Parkinson's treatment with fetal stem cells. We have developed schemes of stem cell treatment for management and control of the disease, which has proven to be effective in case of different forms and at all stages of parkinsonism.
At stages I-III, when uni- and bilateral manifestations of the disease are observed, such as balance disturbances, tremor, mild and moderate rigidity, etc., administration of fetal stem cells is effective in 85% of cases. After the treatment, patients report improvement of stiffness, decrease in shaking while walking and tremor. The dose of antiparkinson drugs can be lowered.
At stage IV (severe stiffness, but the patient still can walk or stand unassisted), stem cell treatment is effective in 65-70% of Parkinson’s disease cases. At stage V (bed- or wheelchair-bound), our therapy helps to improve patient’s quality of life and ease care for the patient due to decreased spasticity and tremor syndrome and improved sleep, normalization of organ and system functioning (heart, lungs, bowels).
In 100% of cases, Parkinson's treatment with fetal stem cells results in psychoemotional improvements. After the stem cell treatment, patients demonstrate positive emotions, improved thinking, more expressive, intelligible and louder speech, and more persistent memory and intellect.
Patient N.N., 62. Parkinson's disease
Patient A.A.N., 72. Akinetic-rigid and tremor-dominant Parkinson’s disease, stage II. Stage II grade 2 essential hypertension. Grade I heart failure. Extensive osteochondrosis
Patient W. H., 67. Akinetic-rigid tremor-dominant Parkinsons’ disease, stage II (Hoehn&Yahr)
||Fetal stem cells treatment results depend on: disease's severity, age of the patient, adherence for the medications and regime. Treatment results, presented on this site, are individual for each clinical case.|